Global Drug Eluting Stent Market Size, Share, Growth, Trends, Company Analysis and Forecast 2020 to 2027

The global drug eluting stent market was valued at USD 5.89 Billion in 2019 and is expected to reach USD 9.10 Billion by year 2026, with a CAGR of 5.75 % during forecast period 2020 to 2027.

The study covers in-depth analysis of drug eluting stents and its extensive use in the cardiovascular diseases. Drug eluting stents are metal stents that are coated with a pharmacologic agent (drug) that is known to suppress restenosis (the reblocking or closing up of an artery after angioplasty due to excess growth inside or at the edge of the stent). Drug eluting stents are usually preferred over bare metal stents for most people. Drug eluting stents are generally to keep the blockage from recurring compared to bare metal stents. One of the major objectives of drug eluting stents is to limit neointimal hyperplasia. The global drug eluting stent market is propelled by number of factors such as rise in the geriatric population, increasing prevalence of cardiovascular diseases, growing acceptance for minimally invasive endovascular surgeries.

Key growth indicators of the drug-eluting stents market, including historical value and volume analysis, pricing analysis, value and supply chain analysis, and Y-o-Y growth trend analysis have been elucidated in the report. Readers can avail unbiased analysis and in-depth information on the drug-eluting stents market that can help them estimate both, qualitative and quantitative growth prospects of the market for the given timeframe.

VRR covers a detailed taxonomy of the drug-eluting stents market, along with an incisive outlook on the competitive scenario. The report profiles a list of companies operating in the drug-eluting stents market, wherein, the product portfolios, technological innovations, geographical expansion, and key growth strategies of these players have been mentioned in detail.

The report on the drug-eluting stents market allows stakeholders to understand key demand trends that end users may seek in the long run, and the appropriate sourcing strategy for the same. For companies involved in the drug-eluting stents market, the report helps understand key end users contributing to demand, allowing them to strategically formulate steps to enhance their sales prospects.

Key players in the global drug eluting market include Terumo Corporation, Biosensors, Abbott Laboratories, Boston Scientific Corporation, Medtronic PLC, Biotronik SE & Co. KG, MicroPort Scientific Corporation

Key Segments

• In terms of product, the polymer-based segment dominated the global drug-eluting stents market in 2019. The segment is expected to maintain its dominance during the forecast period. Expansion of the segment is attributed to the availability of a wide range of polymer-based drug-eluting stents in the market, and their high rate of adoption for coronary interventions across the globe. Furthermore, recent product approvals are likely to boost the segment during the forecast period. In February 2019, Medtronic launched Resolute Onyx 2.0 mm DES in the U.S. This product enabled cardiologists to treat patients with coronary artery disease, and have small vessels that cannot be treated with larger size stent technologies available in the drug-eluting stents market.
• In terms of drug, the sirolimus segment is estimated to expand at a high CAGR during the forecast period. Sirolimus is an extensively used drug for stents. Sirolimus coated drug-eluting stents have less late lumen loss and less angiographic restenosis.
• In terms of generation, the global drug-eluting stents market has been classified into 1st generation, 2nd generation, 3rd generation, and 4th generation. The 3^rd generation drug eluting stents segment is anticipated to hold a notable share of the global drug-eluting stents market by 2027. The 4^th generation DES segment is projected to expand at a high CAGR during the forecast period.
• Based on scaffold, the cobalt-chromium segment is anticipated to dominate the global drug-eluting stents market from 2019 to 2027, which is attributed to an increase in the use of cobalt-chromium stents and several market players manufacturing cobalt-chromium-based stents. Flexibility, long shelf-life, and better biocompatibility of cobalt-chromium-based drug-eluting stents are anticipated to attribute to its leading share of the global market.
• Based on application, the global drug-eluting stents market has been bifurcated into coronary diseases and peripheral vascular diseases. The peripheral vascular diseases segment is likely to gain significant share and offer lucrative opportunities during the forecast period. This is attributed to an increase in the demand for drug-eluting vascular stents for the treatment of peripheral vascular diseases. As per the Cochrane Database Syst Rev 2016, in Western countries, the prevalence of peripheral vascular diseases is increasing among people above 50 years of age.
• In terms of end user, the global drug-eluting stents market has been bifurcated into hospitals and ambulatory surgical centers. The ambulatory surgical centers segment is projected to expand at a notable CAGR due to a shift of coronary interventions from hospitals to ambulatory surgical centers.
• The drug-eluting stents market size and forecast for each of these segments has been provided for the duration of 2016 to 2027. The CAGR of respective segments has also provided for the forecast period from 2020 to 2027, with 2020 as the base year.

Segmentation:

Drug-eluting stents Market by Product

• Polymer-based
  • Biodegradable Polymers
  • Durable Polymers
• Polymer-free

Drug-eluting stents Market by Drug

• Sirolimus
• Paclitaxel
• Zotarolimus
• Everolimus
• Biolimus
• Others

Drug-eluting stents Market by Generation

• 1st Generation
• 2nd Generation
• 3rd Generation
• 4th Generation

Drug-eluting stents Market by Scaffold

• Cobalt-Chromium
• Platinum-Chromium
• Nitinol
• Biodegradable
• Others

Drug-eluting stents Market by Application

• Coronary Diseases
• Peripheral Vascular Diseases

Drug-eluting stents Market by Region

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Research Methodology

The drug-eluting stents market report is a result of unique research methodology, which includes a perfect combination of primary research, secondary research, and expert panel reviews. The data repository for the drug-eluting stents market is updated on a continuous basis, with key stakeholders and their developments tracked at regular intervals.

Secondary sources such as annual reports, company websites, industry white papers, government publications, investor presentations, statistical databases, internal and external proprietary databases, and regulatory databases are generally referred to for developing preliminary market understanding.

Primary research involves interviews and e-mail interactions with C-level executives, KOLs, and regional officers of companies operating in the drug eluting stents market, for unbiased, yet detailed reviews on the drug-eluting stents market across different geographical divisions.

Information obtained from secondary resources and verified by primary resources have contributed to the compilation of the drug-eluting stents market report.